Quiz 3

Question 1

Metformin (Brand, Class, MOA)

Answer 1

Glucophage. Biguanide. Decreases liver glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity.

Question 2

Metformin (Indication, Preg X, Black Box)

Answer 2

T2DM. Not X. Lactic Acidosis.

Question 3

Glyburide (Brand, Class, MOA)

Answer 3

Diabeta. Sulfonylurea (insulin secretagogue). Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver, improves insulin sensitivity in peripheral target site.

Question 4

Glyburide (Indication, Preg X, Black Box)

Answer 4

T2DM. Not X. None.

Question 5

Glipizide (Brand, Class, MOA)

Answer 5

Glucotrol. Sulfonylurea (insulin secretagogue). Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver, improves insulin sensitivity in peripheral target site.

Question 6

Glipizide (Indication, Preg X, Black Box)

Answer 6

T2DM. Not X. None.

Question 7

Pioglitazone (Brand, Class, MOA)

Answer 7

Actos. TZD (thiazolidinedione). Improves insulin sensitivity without increased insulin release from pancreatic beta cells; agonist for PPARgamma receptors, which promotes glucose metabolism.

Question 8

Pioglitazone (Indication, Preg X, Black Box)

Answer 8

T2DM. Not X. CHF (rapid weight gain, dyspnea, edema)

Question 9

Exenatide (Brand, Class, MOA)

Answer 9

Byetta. GLP-1 Receptor Agonist. Resembles GLP-1, which increases glucose-dependent insulin secretion and decreases glucagon secretion. (also increases beta cell production).

Question 10

Exenatide (Indication, Preg X, Black Box)

Answer 10

T2DM. Not X. Thyroid C-cell tumor risk in Bydureon ER (not Byetta IR)

Question 11

Sitagliptin (Brand, Class, MOA)

Answer 11

Januvia. DPP-4 Inhibitor (dipeptidyl peptidase 4). Inhibits DPP-IV enzyme, causing prolonged GLP-1 levels (which increase glucose-dependent insulin secretion from pancreatic beta cells and decrease glucagon secretion from pancreatic alpha cells. decreased glucagon secretion results in decreased hepatic glucose production).

Question 12

Sitagliptin (Indication, Preg X, Black Box)

Answer 12

T2DM. Not X. None.

Question 13

Sitagliptin/Metformin (Brand, Class, MOA)

Answer 13

Janumet. DPP-4 Inhibitor (dipeptidyl peptidase 4)/biguanide. Inhibits DPP-IV enzyme, causing prolonged GLP-1 levels (which increase glucose-dependent insulin secretion and decrease glucagon secretion). Also decreases liver glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity.

Question 14

Sitagliptin/Metformin (Indication, Preg X, Black Box)

Answer 14

T2DM. Not X. Lactic Acidosis.

Question 15

Saxagliptin (Brand, Class, MOA)

Answer 15

Onglyza. DPP-4 Inhibitor (dipeptidyl peptidase 4). Inhibits DPP-IV enzyme, causing prolonged GLP-1 levels (which increase glucose-dependent insulin secretion and decrease glucagon secretion).

Question 16

Saxagliptin (Indication, Preg X, Black Box)

Answer 16

T2DM. Not X. None.

Question 17

Liraglutide (Brand, Class, MOA)

Answer 17

Victoza. GLP-1 receptor agonist (glucagon like peptide 1). Resembles GLP-1, which increase glucose-dependent insulin secretion and decreases glucagon secretion.

Question 18

Liraglutide (Indication, Preg X, Black Box)

Answer 18

T2DM. Not X. Thyroid C-cell tumor risk.